Acute Myeloid Leukemia Therapeutic Pipeline Analysis | Insights into the Latest FDA, EMA, and PMDA Approvals, Breakthroughs, Clinical and Non-Clinical Trials, Emerging Therapies, Treatment Algorithm, and Key Companies In the Domain

As per DelveInsight's assessment, globally, nearly 260+ key pharma and biotech companies are working on 260+ pipeline drugs in the Acute Myeloid Leukemia therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Acute Myeloid Leukemia Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Acute Myeloid Leukemia Therapeutics Market.

The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).

The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Acute Myeloid Leukemia Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Acute Myeloid Leukemia Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Myeloid Leukemia treatment.
Acute Myeloid Leukemia key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Acute Myeloid Leukemia Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Myeloid Leukemia market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Learn more about the report's offerings:
https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

DelveInsight's Report covers around 260+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Acute Myeloid Leukemia Therapeutics Analysis
There are approx. 260+ key companies which are developing the therapies Acute Myeloid Leukaemia. Currently, Gamida Cell has its Acute Myeloid Leukaemia drug candidates in the most advanced stage of clinical development.

Acute Myeloid Leukaemia Emerging Drugs
• Omidubicel: Gamida Cell
• Uproleselan: GlycoMimetics
• ALT 803: ImmunityBio
• BPX-501: Bellic#m Pharmaceuticals
And many more

Some of the key companies in the Major Players in the Acute Myeloid Leukaemia Therapeutics Market include:
GlycoMimetics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Takeda Oncology, Orca Bio, Gilead Sciences, Actinium Pharmaceuticals, Kronos Bio, Bristol-Myers Squibb, ImmunityBio, Bellic#m Pharmaceuticals, TC BioPharm, Syros Pharmaceuticals, Armaceutica, Teva Pharmaceutical Industries, New Epsilon Innovation Limited, MediGene, TC Biopharm, PersonGen BioTherapeutics, Oncoceutics, Janssen Research & Development, LLC, Immune-Onc Therapeutics, Novartis, Jasper Therapeutics, Agastiya Biotech, Poseida Therapeutics, Molecular Partners, Allogene Therapeutics, Allogene therapeutics, and many others

Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Acute Myeloid Leukemia Current Treatment Patterns
4. Acute Myeloid Leukemia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Acute Myeloid Leukemia Late Stage Products (Phase-III)
7. Acute Myeloid Leukemia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Acute Myeloid Leukemia Discontinued Products
13. Acute Myeloid Leukemia Product Profiles
14. Acute Myeloid Leukemia Key Companies
15. Acute Myeloid Leukemia Key Products
16. Dormant and Discontinued Products
17. Acute Myeloid Leukemia Unmet Needs
18. Acute Myeloid Leukemia Future Perspectives
19. Acute Myeloid Leukemia Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.

Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report):
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/acute-myeloid-leukemia-aml-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.